Literature DB >> 10511294

Targeting HDL-mediated cellular cholesterol efflux for the treatment and prevention of atherosclerosis.

G A Francis1, R J Perry.   

Abstract

The hallmark of the atherosclerotic lesion is the overaccumulation of cholesterol in arterial wall cells. As no pathway exists for the degradation of cholesterol in peripheral cells, a mechanism is necessary to prevent its accumulation to toxic levels in these cells and to allow its delivery to the liver for excretion in bile. Promoting this reverse cholesterol transport pathway is believed to be the main cardioprotective action of high density lipoprotein (HDL). The rate-limiting step in this pathway is likely the initial removal of cholesterol from peripheral cells by HDL. The pathway HDL utilizes for inducing efflux of excess cellular cholesterol represents an important and as-yet untapped mechanism to employ for the treatment and prevention of atherosclerotic vascular disease. This review summarizes the potential cardioprotective actions of HDL, the mechanisms of HDL-mediated cellular cholesterol efflux, and evidence that the specific pathway of cholesterol removal by HDL may be enhanced and used as a novel target in the therapy of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10511294     DOI: 10.1016/s0009-8981(99)00103-5

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  3 in total

1.  Visualization of the uptake of high-density lipoprotein by rat aortic endothelial cells and smooth muscle cells in vitro.

Authors:  Wei T Chao; Seng S Fan; Vivian C Yang
Journal:  Histochem J       Date:  2002-05

Review 2.  Vitamin E: action, metabolism and perspectives.

Authors:  E Herrera; C Barbas
Journal:  J Physiol Biochem       Date:  2001-03       Impact factor: 4.158

3.  Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial.

Authors:  Tymon Pol; Claes Held; Johan Westerbergh; Johan Lindbäck; John H Alexander; Marco Alings; Cetin Erol; Shinya Goto; Sigrun Halvorsen; Kurt Huber; Michael Hanna; Renato D Lopes; Witold Ruzyllo; Christopher B Granger; Ziad Hijazi
Journal:  J Am Heart Assoc       Date:  2018-02-01       Impact factor: 5.501

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.